ArticleMedicine2026
Aldehyde reductase as potential measurement for retinitis pigmentosa: A two-sample Mendelian randomization (MR) study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to utilize Mendelian randomization (MR) analysis to investigate potential genetic targets related to aldehyde metabolism in the context of retinitis pigmentosa (RP) and to identify possible therapeutic options. Genome-wide association study data for RP were obtained for MR analysis. We employed various statistical methods, including inverse-variance weighted analysis, to evaluate potential causal associations with RP risk, followed by rigorous sensitivity analysis. Two-sample MR analysis identified a significant causal relationship between aflatoxin B1 (AFB1) aldehyde reductase and the risk of RP, with genetically predicted AFB1 aldehyde reductase contributing to a decreased risk of RP (odds ratio: 0.875; P = .008) based on inverse-variance weighted analysis. Sensitivity analysis suggested no evidence of heterogeneity or horizontal pleiotropy in the observed associations (P > .05). Additionally, the leave-one-out validation confirmed the robustness of these findings without significant alterations. The results from the reverse analysis for the causal relationship between the accidence of RP and AFB1 aldehyde reductase showed no significant statistical differences. Our findings highlighted the role of AFB1 aldehyde reductase in the pathogenesis of RP, proposing it as a promising protective measure for future treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.